ArticleBrain research2008
Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone.
Article in Brain research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 40 citations in OpenAlex.
- Multi-Behavioral Endpoint Testing of an 87-Chemical Compound Library in Freshwater Planarians.Toxicological sciences : an official journal of the Society of Toxicology · 2019Article
- Oxidative Stress in Neurodegenerative Diseases.Molecular neurobiology · 2016Review
- Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions.Neurochemical research · 2016Article
- Long-term evaluation of Leber's hereditary optic neuropathy-like symptoms in rotenone administered rats.Neuroscience letters · 2015Article
- Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.Free radical biology & medicine · 2013Review
- Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.Journal of neural transmission (Vienna, Austria : 1996) · 2012Article
- Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.PloS one · 2012Article
- Mitochondrial optic neuropathy:Eye and brain · 2010Review
- Striatal neuroprotection with methylene blue.Neuroscience · 2009Article
- Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy.Neurotoxicity research · 2009Article
- Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.Clinical interventions in aging · 2009Review
- Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
This is the first report of the in vivo effectiveness of memantine as a neuroprotective agent against rotenone-induced retinal toxicity. We tested the hypothesis that uncompetitive NMDAR blockade with memantine prevents mitochondrial dysfunction-related neurodegeneration in vivo, using a mouse model of retinal ganglion cell layer (GCL) degeneration induced by rotenone, a mitochondrial complex I inhibitor. Rotenone induced an increase in cell death and oxidative stress in GCL compared to controls, and these changes were prevented by the co-administration of memantine. The neurotoxic effect of rotenone was also reflected as a decrease in total cell density in GCL and GCL+nerve fiber layer thickness. These changes were also prevented by co-administration of memantine in a dose-dependent manner. In addition, memantine induced an increase in long-term retinal energy metabolic capacity. The results suggest that NMDAR activation contributes to cell death induced by mitochondrial dysfunction and that uncompetitive NMDAR blockade may be used as a neuroprotective strategy against mitochondrial dysfunction in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.